secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001628280-26-027930
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen gets FDA 'Study May Proceed' letter for refisolone nasal spray in menopausal hot flashes
--------------------------------------------------------------------------------

- FDA allows Vistagen to pursue further Phase 2 clinical development of refisolone in U.S. for vasomotor symptoms due to menopause.
- Exploratory Phase 2a study (N=36): refisolone reduced hot flash frequency by 80% vs 36% placebo; effect seen by week 1 (p<.001).
- Refisolone was well-tolerated with no serious drug-related adverse events in the Phase 2a study conducted in Mexico.
- Company cites large unmet need: ~75% of women in America experience hot flashes during menopausal transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026027930/0001628280-26-027930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026027930/vtgn-20260422.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-027930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer